Medicine in the post-genomic era
Genome Medicine publishes peer-reviewed research articles, new methods, software tools, reviews and comment articles in all areas of medicine studied from a post-genomic perspective. Areas covered include, but are not limited to, disease genomics (including genome-wide association studies and sequencing-based studies), disease epigenomics, pathogen and microbiome genomics, immunogenomics, translational genomics, pharmacogenomics and personalized medicine, proteomics and metabolomics in medicine, systems medicine, and ethical, legal and social issues.
- Rebecca Furlong, PhD, Genome Medicine
- Louisa Flintoft, PhD, Genome Medicine
Christoph Plass and colleagues review advances in methylome profiling across cancer types, and discuss how the detection of different methylation subgroups can inform our understanding of cancer development as well as clinical management.
A comprehensive genome-scale study of multiple solid tumors showed that hypomethylated blocks are a universal feature of common solid tumors and occur early in malignancy.
An analysis of phenotypic similarity between 4,869 human diseases and 1,667 drugs suggests possible contraindications and provides insight into mechanisms of disease and drug side effects.
A systems biology approach comparing muscle transcriptional profiles in the chronic cigarette smoke guinea pig model and COPD patients suggests the involvement of CXCL10 and CXCL9 in muscle wasting.
Tim Spector and colleagues review recent epigenetic studies of monozygotic twins with discordance for a variety of diseases including cancer, autoimmune disorders and neurological diseases.
It is a challenge to assess whether rare and patient-specific mutations are cancer drivers. The algorithm DawnRank prioritizes altered genes on a single patient level.
Susanne Haga and colleagues propose four options for the development of patient-friendly formats for genetic and genomic test reports to promote patients' understanding of their test results.
An integrated approach to predict and validate novel anti-cancer drug targets, with demonstration of strong anti-proliferative effects of predicted targets.
Latest articles from Genome Biology
Genome Biology 2014, 15:431
Genome Biology 2014, 15:R100
Genome Biology 2014, 15:R70
Genome Biology 2014, 15:453
From the blog
- 27 June 2014
- A new test to predict breast cancer risk